DRI Capital raises $1.45bn for royalty deals
This article was originally published in Scrip
Executive Summary
DRI Capital has raised $1.45bn in private equity for a fund called Drug Royalty III, which gives the Canadian firm $3bn in drug royalty buying capacity when its new cash is combined with available debt.